COMPASS Pathways plc (CMPS)

Market Cap	271.63M
Revenue (ttm)	n/a
Net Income (ttm)	-144.32M
Shares Out	68.42M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,166,562
Open	3.910
Previous Close	3.920
Day's Range	3.900 - 4.200
52-Week Range	3.855 - 12.750
Beta	2.25
Analysts	Strong Buy
Price Target	33.60 (+746.35%)
Earnings Date	Oct 31, 2024

About CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS
• Website: https://compasspathways.com

Analyst Forecast

According to 6 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price forecast is $33.6, which is an increase of 746.35% from the latest price.

Price Target

$33.6

(746.35% upside)

Analyst Consensus: Strong Buy